{"disease":{"id":"muscular-dystrophy","name":"muscular dystrophy"},"drugs":{"marketed":[{"drug_id":"golodirsen","indication_name":"Duchenne muscular dystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyondys 53","generic_name":"GOLODIRSEN","company_name":"Sarepta","drug_phase":"marketed","molecular_target":"exon 53 of dystrophin pre-mRNA","drug_class":"Antisense Oligonucleotide [EPC]","quality_score":66,"revenue":"400","mechanism":"Vyondys 53 works by binding to specific RNA sequences to prevent the production of a faulty dystrophin protein."},{"drug_id":"casimersen","indication_name":"Duchenne muscular dystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amondys 45","generic_name":"CASIMERSEN","company_name":"Sarepta","drug_phase":"marketed","molecular_target":"exon 53 of dystrophin pre-mRNA","drug_class":"Antisense Oligonucleotide [EPC]","quality_score":65,"revenue":"400","mechanism":"Amondys 45 works by binding to specific RNA sequences to prevent the production of a faulty protein that causes Duchenne muscular dystrophy."},{"drug_id":"eteplirsen","indication_name":"Duchenne muscular dystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exondys 51","generic_name":"ETEPLIRSEN","company_name":"Sarepta","drug_phase":"marketed","molecular_target":"exon 51 of dystrophin pre-mRNA","drug_class":"Antisense Oligonucleotide [EPC]","quality_score":59,"revenue":"300","mechanism":"Exondys 51 binds to specific RNA sequences to prevent the skipping of exon 51 during dystrophin mRNA splicing."},{"drug_id":"vamorolone","indication_name":"Duchenne muscular dystrophy (DMD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Agamree","generic_name":"VAMOROLONE","company_name":"Catalyst Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Agamree works by inhibiting the activity of pro-inflammatory enzymes, reducing muscle damage and inflammation in Duchenne muscular dystrophy."},{"drug_id":"ataluren","indication_name":"Duchenne muscular dystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Translarna","generic_name":"ATALUREN","company_name":"PTC Therapeutics International Limited","drug_phase":"marketed","molecular_target":"Flavin reductase (NADPH)","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"viltolarsen","indication_name":"Duchenne muscular dystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viltepso","generic_name":"VILTOLARSEN","company_name":"Nippon Shinyaku","drug_phase":"marketed","molecular_target":"exon 53 of dystrophin pre-mRNA","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Viltepso works by binding to exon 53 of dystrophin pre-mRNA, allowing for the production of a partially functional dystrophin protein."},{"drug_id":"deflazacort","indication_name":"Duchenne muscular dystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emflaza","generic_name":"DEFLAZACORT","company_name":"Ptc Therap","drug_phase":"marketed","molecular_target":"","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":"Emflaza works by mimicking the effects of cortisol, a natural hormone produced by the body, to reduce inflammation and suppress the immune system."},{"drug_id":"givinostat","indication_name":"Duchenne muscular dystrophy (DMD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duvyzat","generic_name":"GIVINOSTAT","company_name":"Italfarmaco Spa","drug_phase":"marketed","molecular_target":"","drug_class":"Histone Deacetylase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Duvyzat works by blocking enzymes that compact chromatin and silence genes."}],"pipeline":[{"drug_id":"fordadistrogene-movaparvovec","indication_name":"Duchenne Muscular Dystrophy (early-stage)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"fordadistrogene movaparvovec","generic_name":"fordadistrogene-movaparvovec","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Dystrophin gene (DMD); AAV9 receptor (AAVR)","drug_class":"Gene therapy; In vivo gene delivery","quality_score":null,"revenue":null,"mechanism":"Fordadistrogene movaparvovec delivers a functional dystrophin gene via AAV9 vector to restore muscle protein expression in Duchenne muscular dystrophy."}],"offLabel":[],"totalMarketed":8,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT04972604","title":"CureDuchenne Link®: A Resource for Research","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"CureDuchenne","has_results":false},{"nct_id":"NCT00004568","title":"Study of Inherited Neurological Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT04012671","title":"A Registered Cohort Study on Duchenne Muscular Dystrophy","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Ning Wang, MD., PhD.","has_results":false},{"nct_id":"NCT05102916","title":"Swiss Registry for Neuromuscular Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Bern","has_results":false},{"nct_id":"NCT05295277","title":"Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Bionano Genomics","has_results":false},{"nct_id":"NCT06539169","title":"FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT03443115","title":"Duchenne Muscular Dystrophy Heart Study","phase":"","overall_status":"UNKNOWN","enrollment_count":700,"lead_sponsor_name":"Hôpital Cochin","has_results":false},{"nct_id":"NCT04120168","title":"Study Determining the Frequency of Duchenne Muscular Dystrophy and Late-onset Pompe Disease","phase":"","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Turkish Society of Pediatric Gastroenterology, Hepatology and Nutrition","has_results":false},{"nct_id":"NCT01484678","title":"Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy","phase":"","overall_status":"RECRUITING","enrollment_count":550,"lead_sponsor_name":"University of Florida","has_results":false},{"nct_id":"NCT02466217","title":"Phenomics in Autoimmune and Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":537,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07511920","title":"A Multicenter Cohort Study of Duchenne and Becker Muscular Dystrophy in Western Chinese Children","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"West China Second University Hospital","has_results":false},{"nct_id":"NCT06270719","title":"An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":500,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07467187","title":"Invasive Home Ventilation in Denmark","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":450,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05967351","title":"A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04583917","title":"Brain Involvement in Dystrophinopathies Part 1","phase":"","overall_status":"COMPLETED","enrollment_count":377,"lead_sponsor_name":"Great Ormond Street Hospital for Children NHS Foundation Trust","has_results":false},{"nct_id":"NCT03179631","title":"Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":360,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT04668716","title":"Brain Involvement in Dystrophinopathies Part 2","phase":"","overall_status":"COMPLETED","enrollment_count":339,"lead_sponsor_name":"Great Ormond Street Hospital for Children NHS Foundation Trust","has_results":false},{"nct_id":"NCT02369731","title":"Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)","phase":"","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"PTC Therapeutics","has_results":false},{"nct_id":"NCT03760029","title":"A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy","phase":"NA","overall_status":"COMPLETED","enrollment_count":312,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06606340","title":"A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":300,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06711692","title":"The U.K. NorthStar Clinical Network","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT07127978","title":"A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"ITF Therapeutics LLC","has_results":false},{"nct_id":"NCT01247207","title":"Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"PTC Therapeutics","has_results":false},{"nct_id":"NCT01753804","title":"A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.","phase":"","overall_status":"TERMINATED","enrollment_count":269,"lead_sponsor_name":"BioMarin Pharmaceutical","has_results":false},{"nct_id":"NCT05397470","title":"Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":260,"lead_sponsor_name":"Fulcrum Therapeutics","has_results":true},{"nct_id":"NCT06366815","title":"phenotypeS in Non Ambulant Duchenne Muscular Dystrophy","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT01826487","title":"Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT02500381","title":"Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":228,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02104921","title":"Innovative Ultrasound Technology in Neuromuscular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":223,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT03882827","title":"Natural History of Duchenne Muscular Dystrophy","phase":"","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Genethon","has_results":false},{"nct_id":"NCT02090959","title":"An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":219,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT03513367","title":"The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory :PedsQLTM.","phase":"","overall_status":"UNKNOWN","enrollment_count":210,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT04475926","title":"A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":205,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06911190","title":"Ten Year Follow-up in FSHD: the FOCUS 3 Study","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT06579859","title":"Development of a Registry to Assess Natural History in Duchenne Muscular Dystrophy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05102799","title":"MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT02851797","title":"Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":179,"lead_sponsor_name":"Italfarmaco","has_results":true},{"nct_id":"NCT00592553","title":"Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT00847379","title":"Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":173,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT04461561","title":"Using NPT to Evaluate Providing PPC as ELNEC-PPC WBT for Nurses","phase":"NA","overall_status":"UNKNOWN","enrollment_count":172,"lead_sponsor_name":"Altoosi University College","has_results":false},{"nct_id":"NCT03532542","title":"An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":171,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03039686","title":"Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":166,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03603288","title":"Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":161,"lead_sponsor_name":"Santhera Pharmaceuticals","has_results":false},{"nct_id":"NCT03992430","title":"A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05066633","title":"The Efficacy and Safety of Metoprolol as add-on Treatment to Standard of Care in Preventing Cardiomyopathy in Patients With DMD","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Medical University of Gdansk","has_results":false},{"nct_id":"NCT05712447","title":"Duchenne Muscular Dystrophy Video Assessment Registry","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"The Emmes Company, LLC","has_results":false},{"nct_id":"NCT05237973","title":"Investigational Use of Neuromuscular Ultrasound","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT06507215","title":"Dysferlinopathy Protein in Peripheral Blood Monocytes.","phase":"","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}